Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1998-02-10
2000-12-05
Salimi, Ali
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4242301, 4242041, 424 931, 424 9371, 514 15, 530323, 5303887, 53038875, A61K 3912, A61K 39245, A61K 3800, C07K 1600
Patent
active
06156317&
ABSTRACT:
The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8.sup.+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent cytomegalovirus (HCMV) infection. The peptides are capable of activating CTLs and CTLp's in the absence of active viral replication, and thus are useful for eliciting a cellular immune response against HCMV by normal and immunodeficient subjects. Polypeptide and lipopeptide vaccines, with and without adjuvants, also are disclosed.
REFERENCES:
patent: 5075213 (1991-12-01), Pande et al.
patent: 5405940 (1995-04-01), Boon et al.
patent: 5470730 (1995-11-01), Greenberg et al.
Vitiello et al. 1995, J. Clin. Invest., vol. 95, pp. 341-349, Jan. 1995.
Wills, M.R, et al.: "The human CTL response to Cytomegalovirus is dominated by structural protein," J. Virology, 70(11): 7569-7579, (1996).
Tsunoda, T., et al.: "Seriologically identically HLA B35 alleles which do not cross-present minimal cytotoxic epitopes to CD8+ CTL," J. Cell. Biochem., vol. Suppl.0(19A): 298 (1995) Abstr. No. J2-218.
Diamond, D.J., et al. . . . : "Development of a candidate HLA A*0201 restricted peptide based vaccine against HCMV infection," Blood, 90(5): 1751-1767 (1997).
Deres, K., et al. : "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," Nature, 342: 561-564 (1989).
Gonczol E., et al.: "Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate," Vaccine, 12(13): 1080-1085 (1995).
Khattab, B. A., et al.: "Three T-Cell Epitopes Within the C-Terminal 265 Amino Acids of the Matrix Protein pp65 of Human Cytomegalovirus Recognized by Human Lymphocytes," Journal of Medical Virology, 52:68-76 (1997).
Ogg, G. H., et al. "HLA-peptide tetrameric complexes," Immunology, 10:393-396 (1998).
Pande, H., et al.: "Human Cytomegalovirus Strain Towne pp65 Gene: Nucleotide Sequence and Expression in Escherichia coli," Virology, 182: 220-228 (1991).
Parker, Kenneth C., et al: "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," Journal of Immunology, 152: 163-175 (1994).
Rammensee et al. , "Immunogenetics ", 41(4): 178-228 (1995).
Livingston et al., J. Immunol. 159: 1383-1392 (1997).
Quinnan et al., "HLA-Restricted T-Lymphocyte and Non-T-Lymphocyte Cytotoxic Responses Correlate with Recovery from Cytomegaloviru Infection in Bone-Marrow-Transplant Recipients", The New England Journal of Medicine, Cytomegalovirus Infection 307(1): 7-13 (1982).
Borysiewicz et al., "Human Cytomegalorvirus-Specific Cytotoxic T Lymphocytes: Requirements for in vitro Generation and Specificity", Eur. J. Immunol. 13:804-809 (1983).
Clark et al., "Isolation and Partial Chemical Characterization of a 64,000-Dalton Glycoprotein of Human Cytomegalovirus", Journal of Virology, Notes 49(1):279-282 (1984).
Forman et al., "A 64,000 Dalton Matrix Protein of Human Cytomegalovirus Induces In Vitro Immune Responses Similar to Those of Whole Viral Antigen", The Journal of Immunology, 134(5):3391-3395 (1985).
Meyers et al., "Risk Factors for Cytomegalovirus Infection After Human Marrow Transplantation", The Journal of Infectious Diseases 153(3):478-488 (1986).
Miller et al., "Retrovirus-Mediated Gene Transfer into Human Skin Fibroblasts", Mar. 1988 Meeting at Cold Spring Harbor.
Borysiewicz et al., "Relative Frequency of Stage-Specific CTL Recognizing the 72-kD Immediate Early Protein and Glycoprotein B Expressed by Recombinant Vaccinia Viruses", J. Exp. Med. 168:919-931 (1988).
Miller et al., "Design of Retrovirus Vectors for Transfer and Expression of the Human .beta.-Globin Gene", Journal of Virology 62(11):4337-4345 (1988).
Townsend et al., "Recognition of Influenza Virus Proteins by Cytotoxic T Lymphocytes", Phil. Trans. R. Soc. Lond. B 323:527-533 (1989).
Gelinas et al., "Regulated Expression of the Human .beta.-Globin Gene After Retroviral Transfer into Murine and Human Hematopoietic Cells", Hemoglobin Switching, Part B: Cellular and Molecular Mechanisms, pp. 235-249 (1989).
Pande et al., "Structural Analysis of a 64-kDa Major Structural Protein of Human Cytomegalovirus (Towne): Identification of a Phosphorylation Site and Comparison to pp65 of HCMV (AD169)", Virology 178:6-14 (1990).
Falk et al., "Allele-Specific Motifs Revealed by Sequencing of Self-Peptides Eluted from MHC Molecules", Nature 351:290-296 (1991).
Schmidt et al., "A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow Transplants", The New England Journal of Medicine, 324(15):1005-1011 (1991).
Del Val et al., "Efficient Processing of an Antigenic Sequence for Presentation by MHC Class I Molecules Depends on Its Neighboring Residues in the Protein", Cell 68:1145-1153 (1991).
Penna et al., "Cytotoxic T Lymphocytes Recognize an HLA-A2-Restricted Epitope Within the Hepatitis B Virus Nucleocapsid Antigen", J. Exp. Med. 174:1565-1570 (1991).
Goodrich et al., "Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease After Allogenei Bone Marrow Transplantation", The New England Journal of Medicine 325(23):1601-1607 (1991).
Reusser et al., "Cytotoxic T-Lymphocyte Response to Cytomegalovirus After Human Allogeneic Bone Marrow Transplantation: Pattern of Recovery and Correlation With Cytomegalovirus Infection and Disease", Blood 78(5):1373-1380 (1981).
Riddell et al., "Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones", Science 257:238-241 (1992).
Missale et al., "HLA-A31 and HLA-Aw68-Restricted Cytotoxic T Cell Responses to a Single Hepatitis B Virus Nucleocapsid Epitope During Acute Viral Hepatitis", J. Exp. Med. 177:751-762 (1993).
Gilbert et al., "Selective Interference with Class I Major Histocompatibility Complex Presentation of the Major Immediate-Early Protein Following Infection with Human Cytomegalovirus", Journal of Virology 67(6):3461-3469 (1993).
Bertoletti et al., "Definition of a Minimal Optimal Cytotoxic T-Cell Epitope within the Hepatitis B Virus Nucleocapside Protein", Journal of Virology 67(4):2376-2380 (1993).
Kast et al., "Human Leukocyte Antigen-A2. 1 Restricted Candidate Cytotoxic T Lymphocyte Epitopes of Human Papillomavirus Type 16 E6 and E7 Proteins Identified by Using the Processing-Defective Human Cell Line T2", Journal of Immunotherapy 14:115-120 (1993).
Ralston et al., "Characterization of Hepatitis C Virus Envelope Glycoprotein Complexes Expressed by Recombinant Vaccinia Viruses", Journal of Virology 67(11):6753-6761 (1993).
Goodrich et al., "Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant", Annals of Internal Medicine 118:173-178 (1993).
Winston et al., "Ganciclovir Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Bone Marrow Transplant Recipients", Annals of Internal Medicine 118:179-184 (1993).
Riddell et al., "Therapeutic Reconstitution of Human Viral Immunity by Adoptive Transfer of Cytotoxic T Lymphocyte Clones", CurrentTopics in Microbiology and Immunology 189:9-34 (1994).
Li et al., "Recovery of HLA-Restricted Cytomegalovirus (CMV)-Specific T-Cell Responses After Allogeneic Bone Marrow Transplant: Correlation with CMV Diseas and Effect of Ganciclovir Proophylaxis", Blood 83(7):1971-1979 (1994).
Johnson et al., "Induction of a Major Histocompatibilty Complex Class I-Restricted Cytotoxic T-Lymphocyte Response to a Highly Conserved Region of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120 in Seronegative Humans Immunized with a Candidate HIV-1 Vaccine", Journal of Virology 68(5):3145-3153 (1994).
Speir et al., "Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis", Science 265:391-394 (1994).
McLaughlin-Taylor et al., "Identification of the Major Late Human Cytomegalovirus Matrix Protein pp65 as a Target Antigen for CD8+ Virus-Specific Cytotoxic T Lymphocytes", Journal of Medical Virology 43:103-110 (1994).
Vitiello et al., "Development of a Lipopeptide-based T
Diamond Don Jeffrey
York Joanne
City of Hope
Salimi Ali
LandOfFree
Immuno-reactive peptide CTL epitopes of human cytomegalovirus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immuno-reactive peptide CTL epitopes of human cytomegalovirus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immuno-reactive peptide CTL epitopes of human cytomegalovirus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-958961